CSA BioTech, a Brigham Young University (BYU) spinoff, is an emerging biopharmaceutical company focused on commercializing a novel class of patented compounds known as ceragenins or CSAs. These compounds have broad-spectrum activity mimicking those of endogenous antimicrobial peptides such as LL-37. CSAs, however, are not peptides; rather synthetic small molecules that can be manufactured at large scale and are not subject to proteolytic degradation. CSAs are anti-inflammatory, immune-stimulant antimicrobials (including Multi Drug Resistant strains and carbapenem resistant strains). The technology is the subject of two multimillion-dollar NIH funded research grants. The focus areas are in animal health, food safety products, pharmaceuticals, and consumer products. There are hundreds of uses and applications of CSAs.

Ceragenins or 'CSAs' have little or no risk of toxicity, even at doses much higher than would ever be needed. CSAs method of action is membrane disruption; because the innate immune system has survived millions of years without mutational resistance, this method of action is not subject to the diminishing efficacy of repeated use. CSAs can be formulated many ways; over 144 different CSA compounds have been synthesized. These compounds can be added to topical creams and gels, encapsulated for digestion, or used to coat medical devices, giving them their own version of an immune system.

CSA BioTech’s ceragenin technology consists of formulations of novel, broad-spectrum antimicrobial compounds also known as ceragenins, cationic selective antimicrobials or CSAs. Ceragenins have shown excellent, rapid bactericidal, fungicidal and virucidal results against a wide variety of pathogens, including gram-positive and gram-negative bacteria, and even multi-drug resistant strains of bacteria such as Methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa. The LifeGuardTM coating technology uses the ceragenin compound CSA-13 as its active ingredient and is designed for use on medical devices to provide long-lasting antimicrobial protection far superior to existing alternatives. Further, CSA-13 has been shown in existing testing to effectively prevent the formation of biofilms, an attribute that no known existing antimicrobial product is capable of accomplishing.

Ceragenin compounds are a class of cholic-acid based compounds discovered by Professor Paul B. Savage, Ph.D. at Brigham Young University in Provo, Utah. Ceragenins are non-peptide functional mimics of endogenous antimicrobial peptides such as cathelicidin (LL-37) and the alpha and beta defensins. N8 Medical has licensed the exclusive rights to the ceragenin compounds for medical device and pharmaceutical applications, excluding ophthalmology applications. The company is offering the ceragenin technology to leading medical device companies for sublicense in certain fields, and is actively engaged in joint development and sublicensing programs with numerous industry leaders. Scientists are also independently developing certain ceragenin-coated medical devices and ceragenin-based pharmaceuticals.